Recent Finacing
Recent Raise
Prevail Therapeutics develops gene therapies using REGENXBIO's NAV AAV9 vector to target lysosomal dysfunction in genetically defined neurodegenerative diseases, including PR001 for GBA-associated Parkinson’s.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Prevail Therapeutics.
